What Rapport Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 4 |
| Sells | 20 | 75 |
| Total trades | 20 | 84 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 90,566 |
| Disposed | 149,624 | 1,286,318 |
| Net activity | −149,624 | −1,195,752 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer | Aug 25 | Open-market sale · S | −18,921 | $49.57 | −$938K | 467,187 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Aug 25 | Open-market sale · S | −16,201 | $51.06 | −$827K | 195,862 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Aug 25 | Open-market sale · S | −20,799 | $50.31 | −$1.05M | 212,063 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Aug 24 | Open-market sale · S | −13,160 | $50.00 | −$658K | 232,862 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Aug 19 | Open-market sale · S | −404 | $49.90 | −$20.2K | 246,022 |
| Ceesay Abraham | Chief Executive Officer | Aug 11 | Open-market sale · S | −5,794 | $48.62 | −$282K | 486,108 |
| Ceesay Abraham | Chief Executive Officer | Aug 11 | Open-market sale · S | −19,500 | $48.04 | −$937K | 491,902 |
| Ceesay Abraham | Chief Executive Officer | Aug 11 | Open-market sale · S | −3,664 | $46.90 | −$172K | 511,402 |
| Ceesay Abraham | Chief Executive Officer | Aug 10 | Open-market sale · S | −8,370 | $46.75 | −$391K | 515,066 |
| Ceesay Abraham | Chief Executive Officer | Aug 10 | Open-market sale · S | −14,171 | $45.97 | −$651K | 523,436 |
| Ceesay Abraham | Chief Executive Officer | Jul 27 | Open-market sale · S | −7 | $42.74 | −$299 | 537,607 |
| Ceesay Abraham | Chief Executive Officer | Jul 27 | Open-market sale · S | −2,203 | $42.11 | −$92.8K | 537,614 |
| Ceesay Abraham | Chief Executive Officer | Jul 14 | Open-market sale · S | −2,729 | $40.57 | −$111K | 539,817 |
| Ceesay Abraham | Chief Executive Officer | Jul 14 | Open-market sale · S | −5,481 | $39.72 | −$218K | 542,546 |
| Gault Cheryl | Chief Operating Officer | Jun 30 | Open-market sale · S | −1,000 | $43.15 | −$43.2K | 149,914 |
| Gault Cheryl | Chief Operating Officer | Jun 30 | Open-market sale · S | −3,308 | $42.17 | −$140K | 150,914 |
| Gault Cheryl | Chief Operating Officer | Jun 30 | Open-market sale · S | −3,792 | $41.39 | −$157K | 154,222 |
| Gault Cheryl | Chief Operating Officer | Jun 30 | Open-market sale · S | −1,900 | $40.09 | −$76.2K | 158,014 |
| Ceesay Abraham | Chief Executive Officer | Jun 29 | Open-market sale · S | −876 | $40.34 | −$35.3K | 548,027 |
| Ceesay Abraham | Chief Executive Officer | Jun 29 | Open-market sale · S | −7,344 | $39.77 | −$292K | 548,903 |
Loading...